Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02662244 · ClinicalTrials.gov registry record · NA

Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma

A NA study, sponsored by University of California, San Diego.

Completed
Registry status
NA
Development phase
33
Enrollment target

NCT02662244 is a NA study that has completed, run by University of California, San Diego. The registered enrollment target is 33 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02662244, a NA study, has completed, sponsored by University of California, San Diego.

COMPLETED
Registry status
NA
Development phase
33 participants
Enrollment target

Study Summary

Basal cell carcinoma (BCC) is the most common skin cancer worldwide. Although this tumor is rarely life threatening, it is locally destructive and can cause significant cosmetic and functional problems. Standard therapeutic modalities for BCC often result in disfigurement from surgical treatments and recurrences with topical therapies. Thus, there is a need for alternative non-surgical options that are effective, efficient, and have a low risk of side effects. This has led to the emergence of laser investigations for the treatment of BCC due to the ease of treatment, lack of significant downtime, decreased risk of complications, and absence of a surgical scar. The primary objective of this study is to evaluate the safety and efficacy of laser treatment of subjects with BCC on the trunk and extremities. Subjects will receive one treatment with the laser to the BCC. Standard excision will be performed between 30 and 90 days after laser treatment to evaluate resolution of the BCC. A visit for suture removal will be performed as appropriate for the site of the surgery. Standardized photographs and measurements will be taken at the baseline visit, immediately after laser treatment and on the day of excision.

Interventions

  • DEVICE Nd:YAG laser

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2015-09
Est. Completion 2016-09
Phase NA

Sponsor

University of California, San Diego

775 total trials

What the Registry Record Tells You About NCT02662244

The ClinicalTrials.gov registry entry for NCT02662244 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Nd:YAG laser is the first listed.

NCT02662244 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02662244 about?

NCT02662244 is a clinical study titled "Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma". Basal cell carcinoma (BCC) is the most common skin cancer worldwide. Although this tumor is rarely life threatening, it is locally destructive and can cause significant cosmetic and functional problems. Standard therapeutic modalities for BCC often result in disfigurement from surgical treatments an...

What is the current status of trial NCT02662244?

This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2015-09. Estimated completion is 2016-09.

What interventions are being tested in trial NCT02662244?

The interventions under investigation include: Nd:YAG laser (DEVICE).

Who is sponsoring clinical trial NCT02662244?

This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.